ストックスクリーナーアプリを入手
36.98
0.68%
0.25
アフターアワーズ：
37.01
0.03
+0.08%
前日終値:
$36.73
開ける：
$36.92
24時間の取引高:
1.72M
Relative Volume:
0.88
時価総額：
$6.32B
収益：
-
当期純損益:
$-328.94M
株価収益率:
-15.10
EPS:
-2.4483
ネットキャッシュフロー:
$-266.00M
1週間 パフォーマンス:
+1.76%
1か月 パフォーマンス:
+5.03%
6か月 パフォーマンス:
+156.45%
1年 パフォーマンス:
+563.91%
1日の値動き範囲:
$35.92
$37.29
1週間の範囲:
$35.17
$37.29
52週間の値動き範囲:
$4.55
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Compare COGT vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
36.98 | 6.27B | 0 | -328.94M | -266.00M | -2.4483 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | 再開されました | Jefferies | Buy |
| 2025-11-10 | アップグレード | Stifel | Hold → Buy |
| 2025-11-10 | アップグレード | Wedbush | Neutral → Outperform |
| 2025-10-16 | 開始されました | Stifel | Hold |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-11 | ダウングレード | Needham | Buy → Hold |
| 2024-02-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | 開始されました | Citigroup | Buy |
| 2023-12-11 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-12-08 | 開始されました | JP Morgan | Overweight |
| 2023-04-28 | 開始されました | Robert W. Baird | Outperform |
| 2023-03-27 | 再開されました | H.C. Wainwright | Buy |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-06-28 | 開始されました | Guggenheim | Buy |
| 2021-10-11 | 開始されました | H.C. Wainwright | Buy |
| 2021-06-09 | 再開されました | Jefferies | Buy |
| 2020-12-23 | 開始されました | Piper Sandler | Overweight |
| 2020-10-14 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Cogent Biosciences Inc (COGT) 最新ニュース
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results - Investing News Network
Cogent Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cogent Biosciences (NASDAQ:COGT) Releases Earnings Results - MarketBeat
Bezuclastinib NDAs and cash into 2028 at Cogent Biosciences (NASDAQ: COGT) - Stock Titan
Cogent Biosciences 1Q 2026: Net loss $(97.4)M, EPS $(0.53) — 10-Q Summary - TradingView
Biotechnology company Cogent Biosciences, Inc.'s latest financial data shows that as of the end of the first quarter of 2026, the company held a total of $866.4 million in cash and cash equivalents. - Bitget
Cogent Biosciences (COGT) boosts cash to fund bezuclastinib NDAs and launch plans - Stock Titan
Cogent Biosciences Q1 net loss widens on higher expenses - TradingView
Cogent plans two bezuclastinib launches, says cash lasts into 2028 - Stock Titan
BRIEF-Cogent Biosciences Q1 Income From Operations USD -103.607 Million - TradingView
Pictet Asset Management Holding SA Boosts Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
MSN Money - MSN
Cogent Biosciences Inc (NASDAQ:COGT) Shows Bullish Technical Breakout Setup with High Scores - ChartMill
Systemic Mastocytosis (SM) Treatment Market 2026-2035: - GlobeNewswire
Systemic Mastocytosis (SM) Treatment Market 2026-2035: Industry to More Than Double in Size, Led by Sanofi, AdvaCare Pharma, and Cogent Biosciences - Yahoo Finance
Teachers Retirement System of The State of Kentucky Invests $1.33 Million in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Sees Large Drop in Short Interest - MarketBeat
Cogent Biosciences (COGT) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Cogent Biosciences prices equity offering and 1.625% convertible senior notes - MSN
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM - MSN
A Look At Cogent Biosciences (COGT) Valuation After New KRAS And ErbB2 Data At AACR 2026 - Sahm
The Technical Signals Behind (COGT) That Institutions Follow - Stock Traders Daily
[ARS] Cogent Biosciences, Inc. SEC Filing - Stock Titan
Cogent Biosciences (NASDAQ: COGT) details 2026 proxy, pivotal bezuclastinib wins and $901M cash - Stock Titan
COGT (Cogent Biosciences Inc.) reports wider Q4 2025 loss than consensus analyst estimates, with shares dipping 0.36 percent in today's trading.Market Buzz Alerts - Xã Thanh Hà
Cogent Biosciences reports selective pan-KRAS inhibitor CGT-1263 - BioWorld News
Cogent Biosciences (NASDAQ:COGT) Shares Cross Above Fifty Day Moving AverageShould You Sell? - MarketBeat
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors at the 2026 American Society of Clinical Oncology Annual Meeting - Investing News Network
Cogent’s positive tumor trial lands an oral presentation at ASCO - Stock Titan
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - marketscreener.com
Cogent Biosciences Announces Oral Presentation of Positive - GlobeNewswire
Analysts Expect Breakeven For Cogent Biosciences, Inc. (NASDAQ:COGT) Before Long - 富途牛牛
HC Wainwright & Co. Reiterates Cogent Biosciences (COGT) Buy Recommendation - MSN
Cogent Biosciences (COGT): Billionaire Stan Druckenmiller admires upside potential of this stock - MSN
Cogent Bio (COGT) Stock: Invest or Wait? (+2.93%) 2026-04-18Fast Rising Stocks - Xã Thanh Hà
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 - Sahm
Is AACR 2026 KRAS and ErbB2 Data Altering The Investment Case For Cogent Biosciences (COGT)? - Sahm
Cogent Biosciences (COGT) Showcases Promising Data at AACR Annua - GuruFocus
Precision Trading with Cogent Biosciences Inc. (COGT) Risk Zones - Stock Traders Daily
Revenue Check: What is the long term forecast for Cogent Biosciences Inc stockSell Signal & Reliable Entry Point Alerts - baoquankhu1.vn
Does Bezuclastinib’s Real-Time FDA Review and NDA Filing Change The Bull Case For Cogent Biosciences (COGT)? - Yahoo Finance
Cogent Biosciences Inc (COGT) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):